Fostamatinib Disodium


Fostamatinib, sold under the brand names Tavalisse and Tavlesse, maybe a tyrosine kinase inhibitor medication for the treatment of chronic immune thrombocytopenia (ITP). In fact, the drug is administered by mouth. Fostamatinib blocks the activity of the enzyme spleen tyrosine kinase (SYK). This enzyme stimulates parts of the system. By blocking SYK’s activity, fostamatinib reduces the immune system’s destruction of platelets; allowing the platelet count to rise; which also reduces the likelihood of excessive bleeding. Fostamatinib may be a drug wont to treat adults with low platelet count; thanks to chronic immune thrombocytopenia (ITP) when a previous treatment for ITP has not worked tolerably. Chronic immune thrombocytopenia is an autoimmune bleeding disorder where the blood doesn’t clot because it should be due to a coffee platelet count.

In fact, the US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Experts have also approved Fostamatinib for medical use within us in April 2018. Moreover, the FDA granted the appliance for fostamatinib an orphan drug designation and granted the approval of Tavalisse to Rigel Pharmaceuticals. Experts have also approved Fostamatinib for medical use within the European Union in January 2020.

The tablets are formulated as fostamatinib disodium hexahydrate, a disodium hexahydarte salt, and maybe a prodrug of the active compound tamatinib (R-406), which is an inhibitor of the enzyme spleen tyrosine kinase (Syk), hence it is an syk inhibitor. Syk may be a protein tyrosine kinase related to various inflammatory cells, including macrophages, which are presumed to be the cells liable for ITP platelet clearance. When FcγRs I, IIA, and IIIA bind to their ligands, the receptor complex becomes activated and triggers the phosphorylation of the immunoreceptor-activating motifs (ITAMs). This results in various genes becoming activated, which causes a cytoskeletal rearrangement that mediates phagocytosis in cells of the monocyte/macrophage lineage. Because Syk plays a crucial role in FcγR-mediated signal transduction and inflammatory propagation, it’s considered an honest target for the inhibition of varied autoimmune conditions, including atrophic arthritis and lymphoma.

Fostamatinib comes as a tablet to require orally. In fact, it is usually crazy or without food twice daily. Take fostamatinib at around the same time(s) a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to elucidate any part you are doing not understand. Take fostamatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may have to scale back, interrupt, or discontinue your treatment if you experience certain side effects or counting on your treatment response. If your number of platelets (platelet count) doesn’t increase to a particular level after 12 weeks of treatment, your doctor may need to discontinue your treatment. Talk to your doctor about how you’re feeling during your treatment.

Side effects

  • Diarrhoea
  • Nausea
  • Dizziness
  • Rash
  • abdominal pain
  • fatigue

If you experience any of those symptoms, call your doctor immediately or get emergency medical treatment:

  • severe diarrhoea
  • headache, confusion, dizziness, pain, or shortness of breath
  • pain within the upper right a part of the stomach
  • yellowing of the skin or eyes
  • dark coloured urine
  • Nausea
  • vomiting